In a report released today, Kelly Motta from KBW maintained a Hold rating on Banner (BANR – Research Report), with a price target of $75.00. The company’s shares closed yesterday at $59.68.

The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a rare disease that affects the entire body and produces a wide range of ...